Using Atogepant tablets to prevent migraines in teens aged 12 to 17

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and safety of Atogepant, an oral medication, in preventing chronic migraines in adolescents aged 12 to 17 years. Participants will be randomly assigned to receive either Atogepant or a placebo, with neither the participants nor the researchers knowing which treatment is being administered (double-blind). The study aims to assess adverse events and changes in disease activity over the treatment period. It is designed to provide insights into how well Atogepant can reduce the frequency of migraine attacks in this age group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.
* During the last 28 days of the screening/baseline period, and as per eDiary:

  * Participant must have completed the eDiary for a minimum of 20 out of 28 days.
  * Participant has \>= 15 headache days.
  * Participant has \>= 8 migraine days.

Exclusion Criteria:

* Clinically significant hypertension per investigator's judgment.
* History of any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease.

Where it's running

• Rehabilitation and Neurological Services /ID# 270782
  Huntsville, Alabama, United States Recruiting
• Preferred Research Partners /ID# 270389
  Little Rock, Arkansas, United States Recruiting
• Advanced Research Center /ID# 270257
  Anaheim, California, United States Recruiting
• Neuro Pain Research Center /ID# 271048
  Fresno, California, United States Recruiting
• Alliance for Research Alliance for Wellness /ID# 270398
  Long Beach, California, United States Recruiting
• Excell Research /ID# 270258
  Oceanside, California, United States Recruiting

+16 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nebulized dexmedetomidine for early chronic migraine

  This study tests whether inhaled dexmedetomidine can lessen central sensitization and help prevent chronification in people with early chronic migraine.

  Recruiting Beni-Suef University · Banī Suwayf · NCT07769255

• i-NEED: New migraine drugs database

  This project will collect real-life data to see how new migraine treatments—anti‑CGRP antibodies, gepants, ditans, and a sumatriptan‑naproxen combo—work and how well adults with episodic or chronic migraine tolerate them.

  Recruiting at 2 sites IRCCS San Raffaele Roma · Milan, Italy and 1 other locations · NCT07103694

• Suppressive Functions of Regulatory T Cells in Migraine

  This study tests whether regulatory T cells can help control migraine-related inflammation in adults with chronic migraine.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07067112

• Comparing sphenopalatine block and BOTOX for chronic migraine relief

  This study is testing whether a nerve block or BOTOX injections can help people with chronic migraines feel better.

  Recruiting Cairo University · Cairo · NCT06974617

• Acceptance and Commitment Therapy to reduce disability in adults with chronic migraine

  This trial will test whether adding Acceptance and Commitment Therapy (ACT) to usual care helps adults with chronic migraine improve daily functioning and reduce headache frequency and pain.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT06795867

• Comparing nerve block injections to Botox for chronic migraine relief

  This study tests whether nerve block injections or Botox can help adults with chronic migraines feel better and have fewer migraine days.

  Recruiting Zagazig University · Zagazig, Sharqia Province · NCT06684249

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.